EMERYVILLE, Calif., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company, today announced the closing of the second and final tranche of its previously announced financing. The second tranche of $50 million in a private placement was led by a $25-million investment from Koninklijke DSM N.V. (Royal DSM)(AEX:DSM.AS) with the remaining $25 million contributed by Vivo Capital.
"We are pleased to have the support of key investors like DSM and Vivo in pursuing our growth strategy," said John Melo, Amyris President & CEO. "We've delivered a very strong first half and are on track for our best year ever with more than doubling our product sales and continuing to build on our collaboration agreements while reducing our losses. As a result, later this week we will report one of our best revenue quarters in the company's history since exiting the renewable fuels business."
Amyris is the integrated renewable products company that is enabling the world's leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. More information about the company is available at www.amyris.com.
Amyris Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as expected second quarter and full year 2017 business performance and revenue, including product sales revenue) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to manufacturing capacity at Amyris's Brotas facility, delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on May 15, 2017. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo and No Compromise are registered trademarks of Amyris, Inc. All other trademarks are trademarks of their respective owners.
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 email@example.com firstname.lastname@example.org